Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject

NCT ID: NCT07105124

Last Updated: 2025-08-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-18
• Study Completion Date: 2023-02-15

Brief Summary

A Trial to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics, of Sibeprenlimab Solution Administered Subcutaneously in Chinese Healthy Subjects

Conditions

Healthy Subjects (HS)

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

200mg Sibeprenlimab

200 mg Sibeprenlimab (1 × 1 mL injection)

Group Type: EXPERIMENTAL

Sibeprenlimab

Intervention Type: DRUG

Sibeprenlimab is being developed for the treatment of immunoglobulin A nephropathy (IgAN), an autoimmune glomerulonephritis characterized by the deposition of immunoglobulin (Ig) A-containing immune complexes in the kidney.

400mg Sibeprenlimab

400 mg Sibeprenlimab (1 × 2 mL injection)

Group Type: EXPERIMENTAL

Sibeprenlimab

Intervention Type: DRUG

Sibeprenlimab is being developed for the treatment of immunoglobulin A nephropathy (IgAN), an autoimmune glomerulonephritis characterized by the deposition of immunoglobulin (Ig) A-containing immune complexes in the kidney.

600 mg Sibenlimab

600 mg Sibenlimab (1 × 1 mL injection and 1 × 2 mL injection)

Group Type: EXPERIMENTAL

Sibeprenlimab

Intervention Type: DRUG

Sibeprenlimab is being developed for the treatment of immunoglobulin A nephropathy (IgAN), an autoimmune glomerulonephritis characterized by the deposition of immunoglobulin (Ig) A-containing immune complexes in the kidney.

Interventions

Sibeprenlimab

Sibeprenlimab is being developed for the treatment of immunoglobulin A nephropathy (IgAN), an autoimmune glomerulonephritis characterized by the deposition of immunoglobulin (Ig) A-containing immune complexes in the kidney.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Chinese subject between 18 and 55 years of age, inclusive, at the screening visit.
• Healthy, as determined by pretrial medical evaluation (medical history, physical examination, vital signs, 12-lead electrocardiogram [ECG], and clinical aboratory evaluations), as judged by the investigator.
• Body mass index between 19 and 32 kg/m2, inclusive, and body weight not less than 50 kg at the screening visit.
• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• Screening clinical laboratory test values for IgA, IgG, and IgM must meet the following criteria (the clinical laboratory tests may be repeated once per the discretion of the investigator):

• Serum IgA: ≥ 0.8 g/L
• Serum IgG: ≥ 7.0 g/L
• Serum IgM: ≥ 0.4 g/L

Exclusion Criteria

• Subjects with potential to contribute to pregnancy who do not agree to practice 2 different approved methods of birth control or remain fully abstinent (periodic abstinence [eg, calendar, ovulation, symptothermal, post ovulation methods] or withdrawal are not acceptable methods of contraception) from the time of consent through the end of the subject's participation in the trial and an additional 90 days (biological male subjects) or 30 days (biological female subjects) thereafter. If employing birth control, 2 of the following methods must be used: vasectomy, tubal ligation, intrauterine device, birth control pill, birth control implant, birth control depot injection, birth control patch, condom with spermicide, sponge with spermicide, or occlusive cap (vaginal diaphragm or cervical/vault cap) with spermicide.
• Subjects must also agree not to donate sperm from the time of consent through the end of the subject's participation in the trial and an additional 90 days thereafter.
• Subject has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, blood dyscrasias or other medical disorder, including psychiatric disorders, cirrhosis, or malignancy. History of minor skin cancers (not including melanoma) or surgically treated, limited cervical carcinomas (ie, carcinoma in situ) are not exclusionary.
• History of a previous severe allergic reaction with generalized urticaria; angioedema or anaphylaxis.
• Known hypoglobulinemia disorder (ie, common variable immunodeficiency), X-linked agammaglobulinemia, selective IgA deficiency, selective IgM deficiency).
• History of chronic infection (eg, tuberculosis, osteomyelitis, etc) or any infection requiring hospitalization or treatment with antivirals, antibiotics, or antifungal therapy within 30 days prior to administration of IMP.
• Received vaccination during the 30 days prior to administration of IMP.
• Known hepatic (ie, prior or chronic hepatitis C or hepatitis B infection, nonalcoholic steatohepatitis, or cirrhosis) or biliary abnormalities (Gilberts syndrome or asymptomatic gallstones are permitted exceptions).
• A QT interval corrected for heart rate using Fridericia's correction (QTcF) > 450 msec for biological male subjects or > 470 msec for biological female subjects (may be repeated once).
• Previous receipt of antibody or biologic therapy whether licensed or investigational (Ig products, monoclonal antibodies, or antibody fragments) within 30 days prior to dosing or 5 half-lives within the dose of IMP, whichever is longer.
• Concomitant use of marketed or investigational system is immunosuppressive or immunomodulatory medications (eg, corticosteroids, methotrexate, azathioprine, etc. and/or biologics) is prohibited and require a washout period prior to screening (30 days or 5 half-lives, whichever is longer).
• Has received any prescription or nonprescription (over-the-counter [OTC]) medication during the last 30 days or 5 half-lives (of the drug in question), whichever is longer, preceding baseline (Day -1), with the exception of acetaminophen, ibuprofen (or an equivalent nonsteroidal anti-inflammatory drug), hormonal contraceptives, topical medications, vitamins, minerals, traditional Chinese medicines, and dietary or herbal remedies.
• Is participating in another clinical trial of any investigational drug, device, or intervention or has received any investigational medication during the last 3 months or 5 half-lives, whichever is longer, prior to the start of screening.
• History of or current hepatitis or acquired immunodeficiency syndrome or carriers of hepatitis B surface antigen, hepatitis C antibodies, and/or human immunodeficiency virus (HIV) antibodies.
• Subject with a positive drug or alcohol screen test result at screening or Day -1. The drug screen may be repeated once per the discretion of the investigator. The drug screen also screens for cannabinoids, methylenedioxymethamphetamine, and propoxyphene. If a subject tests positive on these tests, inclusion of that subject into the trial will be based on the investigator's judgment with consultation, as needed, with the medical monitor and the sponsor.
• Subject who has a history of alcohol or drug/chemical abuse.
• Subject who has donated > 500 mL or blood within 3 months prior to the start of screening.
• Subject who has donated any plasma within 7 days prior to baseline (Day -1).
• Is an employee of the clinical research team (any sponsor or trial site employee), or has a family member who is an employee of these organizations.
• Subject is judged by the investigator or the medical monitor to be inappropriate for the trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

Sponsor Role: collaborator

Otsuka Beijing Research Institute

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Countries

China

Other Identifiers

417-201-00005

Identifier Type: -

Identifier Source: org_study_id